Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
GlobeNewswire
· *Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with..